Acrivon Therapeutics (NASDAQ:ACRV) Upgraded at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Acrivon Therapeutics (NASDAQ:ACRV) from a neutral rating to a buy rating in a research note issued to investors on Monday, MarketBeat Ratings reports. LADENBURG THALM/SH SH currently has $16.00 price target on the stock.

Several other research firms have also commented on ACRV. Piper Sandler Companies reiterated a buy rating and set a $30.00 price objective on shares of Acrivon Therapeutics in a research report on Friday, September 6th. HC Wainwright reiterated a buy rating and set a $22.00 price objective on shares of Acrivon Therapeutics in a research report on Tuesday, August 13th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of Buy and an average target price of $23.86.

Acrivon Therapeutics Stock Performance

ACRV opened at $7.59 on Monday. The stock has a market capitalization of $234.36 million, a price-to-earnings ratio of -2.65 and a beta of 0.81. The company has a fifty day moving average of $8.19 and a 200 day moving average of $7.68. Acrivon Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $11.90.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.08. On average, equities research analysts forecast that Acrivon Therapeutics will post -2.4 earnings per share for the current year.

Institutional Investors Weigh In On Acrivon Therapeutics

Several institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC lifted its holdings in shares of Acrivon Therapeutics by 78.2% in the 2nd quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock worth $31,093,000 after acquiring an additional 2,353,000 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Acrivon Therapeutics by 58.8% in the 2nd quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock worth $5,503,000 after acquiring an additional 351,397 shares during the last quarter. Sands Capital Ventures LLC lifted its holdings in shares of Acrivon Therapeutics by 28.4% in the 2nd quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company’s stock worth $12,311,000 after acquiring an additional 470,000 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Acrivon Therapeutics in the 2nd quarter worth about $61,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Acrivon Therapeutics in the 2nd quarter worth about $58,000. Institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.